Rociletinib hydrobromide
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
Product Specifications
CAS Number
1446700-26-0
Product Name Alternative
CO-1686 (hydrobromide) ; AVL-301 hydrobromide; CNX-419 hydrobromide
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CO-1686-hydrobromide.html
Purity
98.04
Solubility
DMSO : ≥ 59 mg/mL|H2O : < 0.1 mg/mL
Smiles
C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O.[H]Br
Molecular Formula
C27H29BrF3N7O3
Molecular Weight
636.46
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
